SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL topline results for GPS in AML dominate discussion; the company has said it expects to report results this month after the trial reached its 80th event. Many traders anticipate positive data and speculate about short covering, while others stress that the readout is a binary risk and reject claims of a data leak.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage affecting Outlook, Teams and other services is driving attention, with traders voicing frustration and questioning the reliability of Microsofts enterprise products. Some fear business disruption and speculate about a hack, while others are surprised the shares held relatively steady; hacking claims remain unconfirmed.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels prostate-cancer BLA filing is now expected in mid-2027, later than previously planned, as assay refinement continues amid FDA discussions. Traders are debating the setbacks significance: many criticize managements credibility, especially in light of the CEOs prior share sales, while others view it as a manufacturing and regulatory delay rather than a change to the clinical data.

Modine Manufacturing Co. engages in the provision of thermal management products and solutions. It operates through the Climate Solutions and Performance Technologies business segments. The Climate Solutions segment provides climate-controlled solutions and components, heat transfer products, heating, ventilating, air conditioning and refrigeration products, and data center cooling solutions. The Performance Technologies segment designs and manufactures air- and liquid-cooled technology for vehicular, stationary power, and industrial applications. In addition, the Performance Technologies segment provides thermal solutions to zero-emission and hybrid commercial vehicle and automotive customers, and coating products and application services. The company was founded by Arthur B. Modine on June 23, 1916 and is headquartered in Racine, WI.

Modine Manufacturing Co.

Reports that Samsung is in discussions to acquire Modine have sparked a buyout-focused conversation, though traders are debating whether the deal is real and whether insider selling casts doubt on the speculation.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials quarterly results beat expectations and its next-quarter outlook came in above consensus, but shares fell despite the strong report. Traders are divided between viewing the muted reaction as a sell-the-news or priced-in response and seeing the results and guidance as evidence of continued semiconductor-equipment demand.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly results beat expectations and the company raised its full-year outlook, citing stronger AI-infrastructure demand. Traders broadly welcomed the numbers but debated the muted, volatile share reaction, with some seeing profit-taking or a sell-the-news response and others questioning margins and whether AI orders will translate into sustained growth.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras quarterly results and raised revenue outlook are driving attention, with traders emphasizing accelerating cloud and inference demand and stronger forward guidance despite a GAAP loss. The bullish reaction and short-squeeze talk are countered by concerns about heavy spending, ongoing losses, valuation, and whether the rally can hold.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinals weak quarterly results, sharp margin deterioration, withdrawn 2026 outlook and CFO departure have fueled a steep selloff and concerns about project execution and management; the Hughes Brothers acquisition was also postponed. Traders are split between viewing the drop as justified by business risks and calling it an overreaction, with the authorized buyback and reported net cash position underpinning the bullish case.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis is drawing attention around its Investor Day discussion of commercial launch preparations for ulixacaltamide in essential tremor and relutrigine in developmental epileptic encephalopathies, with two FDA decisions approaching and broader EMERALD trial data also in focus. Traders largely praise the launch planning and market potential, while debating approval and timing risksparticularly for relutrigineand the share-price decline.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

INFQ is drawing attention amid weakness across speculative tech and quantum stocks, with traders debating whether the selloff reflects broader risk-off and forced selling or concerns about the companys execution. The upcoming earnings report is seen as a key test: some traders are buying the dip, while skeptics question commercialization progress and the outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LB Pharmaceuticals Appoints Susan Kozauer As CMO

(RTTNews) - LB Pharmaceuticals Inc. (LBRX), a neuromedicines company, on Tuesday appointed Susan Kozauer as Chief Medical Officer...

LB Pharmaceuticals Names Joseph Miller CFO

(RTTNews) - On Thursday, LB Pharmaceuticals Inc. (LBRX) announced the appointment of Joseph Miller as Chief Financial Officer. LB Pharma is a neuromedicines company dedicated to developing and commercializing therapies that address the multiple dimensions of underserved brain dis...

All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy

LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LB Pharmaceuticals (NASDAQ:LBRX) Raised to "Strong-Buy" at HC Wainwright

HC Wainwright upgraded shares of LB Pharmaceuticals to a "strong-buy" rating in a research note on Monday...

LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week High  - What's Next?

LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 52-Week High - Here's Why...

LB Pharmaceuticals (NASDAQ:LBRX) Trading 5.6% Higher - Time to Buy?

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6% - Time to Buy...

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High - Time to Buy?

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High - Should You Buy...

LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham

LB Pharmaceuticals (NASDAQ:LBRX) is seeking to build a "fully integrated company focused on CNS-related diseases," Chief Executive Officer Heather Turner said during a presentation at a Needham conference hosted by biotech analyst Ami Fadia.

Turner said the company's lead program, LB-102, is a late...

LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 4.5% - Should You Sell?

LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.5% - Here's Why...

LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year High - Should You Buy?

LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 12-Month High - Here's Why...

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

LB Pharmaceuticals Inc

Bullish Sentiment

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Current Price	$42.46
Prev Close	$44.71
Open	$44.37
Dividend Yield	0.00%
50-Day Moving Average	$40.42
Beta	0.98
Avg. Volume	413,799.37
PE Ratio	-9.67

52-Week High	$50.16
52-Week Low	$14.40
Market Capitalization	$1.45B
EPS (Annual)	-$0.9963
Price to Book	3.45
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

LBRX Fundamentals